Vivimed Labs.

- The company is exploring the possibility of reducing debt by diluting less than the current levels to raise money for debt repayment, particularly related to the $39 million mezzanine debt used to buy out a PE investor. - There is mention of subscription warrants expected to bring in funds, which would help reduce debt. - No specific new fundraising through fresh debt or equity is confirmed yet; exploration and negotiations are ongoing. - Efforts are focused on optimizing margins, expanding business, and geographical footprint which may reduce the need for large fundraises. - The company plans to reduce overall consolidated debt by Rs.175-200 Crores over the next 18 months primarily through asset sales (like land sales) and subscriptions rather than fresh debt raising. - A consortium banking arrangement is being worked upon that would release pledged promoter shares, implying some refinancing but no direct mention of fresh fundraising.

- Minimal capex planned for the current year in India, mostly maintenance (Rs.4-5 Crores); major capex was done last year. - Overseas capex expected to be nominal around €3-4 million. - Some capacity ramp-up ongoing, especially at Alathur plant (planned to reach 50% utilization by year-end). - Investment in expanding formulation capacity in Northern India with some capex recently done. - Strategic focus on new product filings, ANDAs in pharma segment, and adding verticals in specialty chemicals. - Exploring opportunistic alliances and joint ventures in specialty chemicals and personal care segments. - Migration of high-cost mezzanine debt to lower cost European bank after March 2018 will reduce financial cost, enabling freeing up capital. - Land sale proceeds and warrant subscriptions expected to support debt reduction and business expansion.

- The company expects overall growth of about 15% year-on-year in sales revenue driven by multiple segments. - Specialty chemicals are projected to grow at 15-20% annually, driven by hair dyes and photochromics with niche patents valid till 2029. - Pharmaceutical segment anticipates 15% growth year-on-year, fueled by new ANDA filings, US generics via Strides Shasun JV, and expanding RoW/markets like CIS and Ukraine. - CDMO business aims to double from $30 million to around $60 million within 13 months based on key client visibility. - US generic formulations, currently minimal (~$5.5 million), expected to increase through selective product filings and leveraging quality compliance advantage. - Alathur plant capacity utilization projected to rise from <20% to at least 50% by the end of FY2018, supporting higher production and sales. - The company is selective in filings, focusing on complex, backward integrated products with high margin potential.

- The company expects approximately 15% year-on-year revenue growth driven by phased ramp-up in formulation business, API growth, and capacity utilization improvements. (Page 11) - Specialty chemicals segment anticipates 15%-20% year-on-year growth backed by new patents valid till 2029 and niche products like photochromic dyes. (Pages 8, 12) - Margins in specialty chemicals and pharmaceuticals improved in Q1 FY2018 and are expected to be sustainable (15-28% margins) with selective US generic filings and backward integration. (Pages 6, 8, 11) - Interest cost expected to decrease substantially post-March 2018 as high-cost mezzanine debt ($39 million at 12% cost) will migrate to European bank loans at ~3.5-4% cost, enhancing net profit and EPS. (Pages 6, 12, 13) - Overall profitability may improve with reduced finance costs, optimized margins, and growth from higher-value products and new filings. (Pages 6, 12, 16) - Debt reduction plans (Rs.175-200 Crores in 18 months) will further strengthen financials supporting earnings growth. (Page 7)

The transcript does not explicitly mention the current or expected order book or pending orders for Vivimed Labs Limited. However, some relevant information related to future business prospects and growth includes: - CDMO business currently at approximately $30 million in sales, expected to double within about 13 months. - Focus on selective filing of ANDAs for US generics, with three products filed in the recent quarter and plans for another four by March 2018. - Anticipated growth of around 15% year-on-year in both specialty chemicals and pharmaceutical segments. - Positive outcomes from regulatory inspections (FDA and Ukraine) expected to enable revenue uptick in formulations. - Expansion in differentiated and higher value-added product portfolio. - Ongoing dialogues for land sale and subscription warrants to reduce debt, indirectly supporting capacity expansion and business growth. No specific numeric order book or pending order values were provided.